Department of pulmonary, University of Ulsan College of Medicine, Asan Medical Center, South Korea Background and Aims: Most patients with chronic obstructive pulmonary disease (COPD) are elderly males. Recently, the use of long acting muscarinic receptor antagonist / long acting beta 2 receptor agonist (LAMA/LABA) combination inhaler therapy is increased in COPD patients. Muscarinic receptor antagonists have anticholinergic actions, which are known to cause or exacerbate dysuria. The aim of this study is that whether LAMA/LABA combination inhaler therapy is a risk factor for voiding dysfunction or not.
Methods:
A cross sectional analysis was performed at a single medical center in South Korea. A total of 105 patients with COPD were enrolled and International Prostate Symptom Score (IPSS) were checked. If the IPSS score was 8 or more, it was defined that there was a meaningful voiding dysfunction.
Results: Mean age is 7 AE years. Already known BPH was 28.6% (n = 30). There were 43 patients (41%) with an IPSS score of less than 8 and 62 patients (59%) with an IPSS score of 8 or more. In univariate logistic analysis, only shorter six minute walk test distance (Odds ratio 0.993, 95% CI 0.988-0.999, P = 0.025) was associated with voiding dysfunction. However, LAMA/LABA combination inhaler therapy (P = 0.485) and LAMA inhaler therapy (P = 0.700) were not a risk factor for voiding dysfunction.
Conclusion:
Voiding dysfunction was relatively common in COPD patients. LAMA inhaler therapy did not seem to be associated with voiding dysfunction. Randomized control trials with larger population will be needed in near future. Methods: We retrospectively analyzed the clinical records of patients who had emphysema on chest CT scans and underwent spirometry more than 2 times at the Shizuoka General Hospital since 2012. Patients were classified into 2 groups: emphysema without airflow limitation (non-COPD group) and emphysema with airflow limitation (COPD group), and the following parameters were compared: background, spirometry, forced oscillation technique, and the 5-year survival rate. In the non-COPD group, the rate of change to COPD was analyzed.
Results: Of the 74 patients who had emphysema on chest CT scans and underwent spirometry more than 2 times, 25 patients (32%) were classified into the non-COPD group and 49 patients (68%) into the COPD group. There was no significant difference in their background at the baseline (age, sex, BMI, Goddard score, and respiratory symptoms), spirometry (FVC, FEV1), diffusing capacity, and 5-year survival rate between the 2 groups. In the non-COPD group, respiratory resistance at baseline was significantly lower and the occurrence of pneumothorax in the 5 years' follow-up was higher than in the COPD group. Eight of 25 patients (32%) changed to COPD after 5 years. These 8 patients had a significantly lower FEV1/FVC at baseline compared to 17 patients who did not change to COPD. Twelve of 17 patients (71%) who did not change to COPD received bronchodilators because of respiratory symptoms.
In patients with emphysema, the background, spirometry, and 5-year survival rate were comparable regardless of the presence of airflow limitation. Thirty two percent patients of emphysema without airflow limitation had changed to COPD after 5 years. Background and Aims: Chronic obstructive pulmonary disease (COPD) is a progressive disease which can lead to some systemic manifestations. Therapy to improve lung function is considered unresponsive to COPD. Assessing and treating COPD are not only based on airflow limitations but also other treatable clinical manifestations. The BODE (Body mass, Obstruction, Dyspnea, Exercise) index is composite marker of disease taking into consideration the systemic nature of COPD. It is one of multidimensional stratification systems which can be used to determine the risk of exacerbations and is also independent predictor of survival in COPD. Pedometer is an effective tool for monitoring and increasing the level of physical activity in healthy people but whether this tool is effective for improving the level of physical activity in COPD patients has not been known. This study aimed to analyze whether pedometer improved the BODE index.
Methods: Randomized controlled trial study in stable COPD outpatients in RS Dr. Moewardi Surakarta from November 1, 2016 to February 15, 2017. The effects of walking exercises using pedometer and control group pre-and post-intervention were analyzed with paired t test (alternative test Wilcoxon). The difference effects of walking exercise between pedometer and control were analyzed by unpaired t test (alternative test
